4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT)

Historical Holders from Q4 2020 to Q3 2025

Symbol
FDMT on Nasdaq
CUSIP
35104E100
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
46.7M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
39.5M
Holdings value
$343M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
126
Number of buys
57
Number of sells
-67
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 9.99% 0% $12.3M -$534K 4.63M -4.17% BVF PARTNERS L P/IL Mar 31, 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $12.1M 4.56M RA Capital Management, L.P. Dec 31, 2024
GOLDMAN SACHS GROUP INC 9.6% $11.7M 4.42M THE GOLDMAN SACHS GROUP, INC. Dec 31, 2024
Novo Holdings A/S 6.8% $27.6M 3.18M Novo Holdings A/S Oct 13, 2025
BlackRock, Inc. 6.6% -15% $26.6M -$4.8M 3.06M -15.3% BlackRock, Inc. Sep 30, 2025
JANUS HENDERSON GROUP PLC 4.9% $5.97M 2.25M JANUS HENDERSON GROUP PLC Dec 31, 2024
Venrock Healthcare Capital Partners III, L.P. 1.5% -81.7% $1.8M -$6.03M 678K -77% Venrock Healthcare Capital Partners III, L.P. Mar 31, 2025
Deep Track Capital, LP 1.32% $1.62M 610K Deep Track Capital, LP Dec 31, 2024

Institutional Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 39.5M $343M -$4.3M $8.69 126
2025 Q2 40.4M $151M -$9.24M $3.71 118
2025 Q1 43.1M $140M -$22.4M $3.23 122
2024 Q4 46.8M $261M -$76.3M $5.57 139
2024 Q3 57.4M $621M -$40.1M $10.81 134
2024 Q2 57.3M $1.2B +$3.36M $20.99 140
2024 Q1 56.2M $1.79B +$449M $31.86 147
2023 Q4 15.9K $322K $20.26 1
2023 Q3 41.9M $533M +$919K $12.73 109
2023 Q2 41.2M $745M +$197M $18.07 99
2023 Q1 30.4M $522M +$35M $17.19 92
2022 Q4 28M $622M +$47.6M $22.21 95
2022 Q3 22.8M $183M -$11.6M $8.04 80
2022 Q2 24.7M $172M +$978K $6.98 83
2022 Q1 25.3M $382M +$19.4M $15.12 70
2021 Q4 23.4M $513M +$75.3M $21.94 72
2021 Q3 18.8M $505M +$68.6M $26.97 61
2021 Q2 16.2M $389M -$3.19M $24.08 52
2021 Q1 15.4M $665M +$47.8M $43.38 64
2020 Q4 13M $536M +$512M $41.45 50